Controlled Expansion of Supercritical Solutions (CESSᵀᴹ) technology produces nanonised ‘designed-for-purpose’ API particles. This enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and improving their bioavailability. Our unique nanoformingᵀᴹ technology also provides novel opportunities in diverse value enhancing drug delivery applications. The patented technology is based on supercritical CO2. The drug solution is expanded through a controlled process to produce pure drug nanoparticles. The process is more controlled than conventional supercritical technologies, and it produces smaller and more uniformly sized particles. This presentation will give an introduction Nanoforms technology and presents case studies to support that Small in powerful.